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In the last century, vaccines, together with the discovery 
of antibiotics have been powerful tools in the management 
of infectious diseases. Both were of particular importance in 
reducing the morbidity and mortality associated with infections 
prevailing in the early 20th century. Whereas antibiotics were 
useful in treating the infection, vaccines worked by priming 
the uninfected individual against future infections. The success 
of vaccination can be seen through numerous examples. The 
World Health Organisation (WHO) was able to certify that 
smallpox had been eradicated in 19801 whereas the European 
Regional Commission for the Certification of the Eradication 
of Poliomyelitis declared the European Region polio-free on 
21 June 2002.2 On the other hand, measles has been reduced 
to very low levels in many regions of the world.3 This led to the 
speculation that such a good result could be extended to other 
diseases. Tuberculosis, human immunodeficiency virus (HIV) 
and malaria are currently three infectious diseases requiring 
urgent attention due to their serious consequences especially 
in less developed countries (Figure 1).   
Preventing and treating malaria
The current measures used to prevent and treat malaria are:
1. Use of suppressive drugs for chemoprophylaxis
2. Pharmacological treatment of malaria cases
3. Vector control 
Although many of the above measures have been successful 
in controlling the spread of malaria in developed countries, the 
problem remains as severe as ever in most of the less developed 
countries. 
Thus, one might argue that the current measures are not 
effective in such countries and innovative ideas are needed 
to combat malaria. This is where pro-vaccine scientists are 
advocating their cause for further vaccine research. Others 
argue that the current measures would be adequate to control 
the infection if used correctly. 
Why develop a malaria vaccine?
“The malaria problem is too great to be overcome by the 
meagre resources traditionally devoted to health.”4 In his 
editorial, Graham Brown suggested that the control of malaria 
should become a national and international priority. Despite 
the various failures seen in trying to develop a good malaria 
vaccine there are two lines of evidence to suggest that such a 
vaccine could be attainable. Naturally acquired immunity can 
be acquired following natural exposure to infection.5 In fact, it 
has been shown that children living in areas of very high malaria 
transmission throughout the year in Africa (holoendemic 
areas) and  who survive up to the age of 10 have a much lower 
probability of developing subsequent severe disease.6 Various 
immunisation strategies have been successful (in whole or in 
part) in inducing protection against experimental infection in 
animal models. Moreover, in humans it has been shown that 
using irradiated sporozoites, one can induce a 95% protection 
lasting for at least 9 months.7 However, these vaccines are strain 
and stage specific.
Using currently available control measures, it has been 
possible to eradicate malaria from a number of countries 
throughout the world without the benefit of a vaccine. These 
include many European countries and the United States.8 
However, these strategies have had far less success in stifling 
malaria from tropical and subtropical countries. The problems 
encountered here include the biology and behaviour of certain 
species of anopheles (the vector responsible for the transmission 
of malaria), intricate immunological and host factors, poverty 
and unsettled political conditions, problems with accessing 
health care facilities and unexpected population movement 
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around  the  world.9  Therefore, in order to achieve better 
control in the latter countries, novel strategies are required. 
The development of an effective vaccine may be one such 
initiative.
A malaria vaccine is unlikely 
in the near future
The prospect of a malaria vaccine has been hampered by 
numerous obstacles. Although there were a number of vaccine 
trials in the past, many of them did not have the desired impact. 
Up to the present day, none of them could be launched as a 
preventive tool. In a study on Gambian infants10, a synthetic 
malaria vaccine, SPf66, was administered in a phase III trial to 
55 children and compared to 32  infants who were given injected 
polio vaccine. It was shown that SPf66 did not protect Gambian 
children against first attacks of malaria or overall incidence of 
malaria infection. 
If a vaccine were to be produced, it should target the 
various pathogenic species of Plasmodium. There are four 
major pathogenic organisms and a good vaccine should protect 
against all of them. However, since Plasmodium falciparum is 
the only one associated with significant mortality, development 
of a vaccine against it might be considered the major target. 
Moreover, there are multiple stages in the life cycle of 
Plasmodium falciparum. Each stage expresses a different 
repertoire of antigens (Table 1) and many of these exhibit 
remarkable polymorphisms. Hence, any vaccine would need to 
include multiple targets which are normally expressed during 
the different stages of the life cycle, but this is very difficult to 
attain.
Organisms from different stages are present in different 
compartments of the host. Some are present intravascularly and 
these stimulate a humoral-mediated immune response. Others 
are present intracellularly and hence stimulate the cellular 
immune system. A good vaccine would induce both the humoral 
and cellular arms of the immune system. Unlike other currently 
available vaccines, such as hepatitis B vaccine and BCG (where 
only one arm is activated), this presents a major challenge.
The success in studies on animal models does not necessarily 
mean that it can be replicated in the human model. Pre-
erythrocytic vaccines are straightforward since immunised 
volunteers can be tested for their ability to prevent blood-stage 
infection after exposure to infected mosquitoes. Even if it were 
shown that such a vaccine was useful, it would still be difficult to 
assess whether it acts similarly in people visiting endemic areas 
or in locals who are constantly exposed to malaria infections. 
Blood stage vaccines are more difficult to evaluate since studies 
will have to assess the level of parasitaemia following infection. 
This exposes volunteers to potential life-threatening infection 
and it is ethically necessary to treat as soon as parasitaemia 
approaches symptomatic levels. Hence, there is no way of 
knowing what level of parasitaemia would otherwise have 
Figure 1:  Areas of the world in which transmission of malaria occurs or where the transmission of malaria is a risk.  
(Source: WHO available at: http://www.who.int/ith/chapter05_m08_malaria.html)
Source: WHO, 2003
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been reached in vaccinated people and those who are given a 
placebo.
Lastly, there has been reduced interest shown by the 
pharmaceutical industry to develop a malaria vaccine. A major 
driving force may be the fact that the vaccine will be used mainly 
in developing countries necessitating that the price of the final 
vaccine be affordable to such populations. Visitors to areas 
affected by malaria are few compared to visitors to other “safer” 
countries and this may result in too small a market. 
Is the development of a malaria vaccine 
a priority?
A number of factors determine the priority of developing 
a vaccine. These are listed in the results of the Joint Global 
Alliance for Vaccines and Immunisation / World Health 
Organisation (GAVI/WHO) meeting held in Geneva in 199911 
and they will be used here to assess the importance of malaria 
vaccine research around the globe.
• What is the magnitude of disease burden?  
 About 40% of the world’s population live in malarious 
areas. It is estimated that 300-500 million people are 
infected by malaria per year and of these 1.5-2.7 million 
die. In the year 2000, malaria was estimated to be the 
cause for the loss of nearly 45 million Disability Adjusted 
Life Years (DALYs) and this accounts for 13% of all 
DALYs associated with infectious diseases.12
• What is the public perception of the disease? 
 Since so many patients are affected per year and the cost 
of disease is so high, the public perception is that if a 
vaccine is not readily produced, then the battle against 
malaria is eventually lost. 
• Is the science sufficiently mature to generate 
rational vaccine candidates? 
 The life cycles of malaria and its vector have been known 
in detail for a number of years. Nowadays, the quest 
is to describe the life cycle at the molecular level and 
find target molecules which can be utilised in vaccine 
development. Malariologists are divided as to the best 
way to produce vaccines. One group believes that the 
parasite antigens already discovered should be enough to 
be able to elicit the immune response.13 Other scientists 
believe that with the sequencing of the parasite’s genome, 
other candidate molecules could be found which may be 
more important than the ones already known.14 
• Are there already candidate vaccines 
 in clinical trials or approaching launch 
 into clinical field trials?
 Numerous malaria vaccines have been tested but none 
have withstood the test of time. For example, a clinical 
trial with a pre-erythrocytic vaccine made up of a fusion 
protein called RTS,S did show protection over the first 
60 days after the third dose of vaccine, but the immunity 
waned with time such that the vaccine did not afford 
significant protection by the end of the study period  of 
105 days.15  The main problem is that different stages of 
the malaria parasite activate different branches of the 
immune system and most of the vaccines tested will only 
activate one arm of the immune system. A promising 
new approach is known as heterologous prime-boosting. 
Using this strategy, an antigen is presented in a series 
of different delivery systems that are administered 
sequentially.16  In fact, animal studies have been carried 
out using a regimen consisting of an initial vaccination 
with a plasmid containing a gene coding for the 
Plasmodium falciparum antigen thrombospondin-related 
adhesion protein (TRAP) as well as several other peptide 
sequences that might provoke an immune response, 
followed by a vaccination with recombinant modified 
vaccinia virus Ankara (MVA), which contained similar 
plasmodium genes.17 It is still to be seen whether the same 
vaccine would be effective in human beings.
• Are there microbiological or parasitological 
factors that make vaccine development difficult? 
 Multiple serotypes or antigens from different stages of 
the parasite must be included in the vaccine. It would 
be physically impossible to include all the possible 
variants in the vaccine. One would have to choose the 
most important ones and these may vary between 
different countries. The result may be that one would 
need a different  malaria vaccine which is specific for the  
geographical area in which he/she lives.
• Are alternative public health measures available?
 In the case of malaria, such measures are available 
but not fully effective. In other instances, they are not 
affordable.
• Does an effective treatment exist? It is common 
knowledge that effective treatment for malaria exists. 
However, the rapid emergence of resistance to treatment 
makes the issue of finding alternative means of control 
more urgent.
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• Is there a traveller’s market in industrialised 
countries? 
 There has been an increase in tourism to tropical 
countries recently. Although still not sufficient, this would 
increase the demand for a vaccine, particularly since the 
current method of chemoprophylaxis is not without its 
hazards.
• Can the vaccine be combined or concomitantly 
delivered with other vaccines? 
 This has not been dealt with yet since there has not 
been an effective vaccine tested on humans as yet. 
Theoretically, this is possible. In fact, it could be 
hypothesised that plasmids coding for antigens from 
different organisms would be genetically engineered and 
incorporated in vectors, such as MVA to deliver antigens 
from more than one organism.
• Can the vaccine be attractive to 
 developing countries? 
 This will need to be addressed once a viable vaccine 
is found. The possibility of administering the vaccine 
parenterally or in 1-2 doses only would be preferable.
• Can the vaccine be cost-effective, assuming 
 optimal implementation? 
 In an analysis comparing the cost-effectiveness of 
vaccines and insecticide impregnation of mosquito 
nets for the prevention of malaria, Graves18 estimated 
that the costs per death averted for a vaccine would be 
US$252 compared with US$771 with nets impregnated 
with insecticide every six months. On the other hand, 
if one had to use an insecticide-impregnated wash-
proof mosquito net (which could be sold for the same 
price as an untreated net), the cost would be nil.19  
Thus, the conclusion that malaria vaccine research 
and development should be the highest priority for 
investment might need to be reconsidered. 
Possible unexpected consequences 
of a malaria vaccine
With all the major benefits of a malaria vaccine, possible 
problems could still arise. After the introduction of a vaccine, 
the pathogen might evolve in response to selection pressure. A 
major concern is “escape mutants” which are variants expressing 
epitopes that vaccinated individuals fail to recognise. This is best 
seen in HIV, where the difficulty with producing a vaccine is the 
high mutation rate of the virus such that new clades arise which 
are not recognised by the host’s immune system.
The worst scenario is seen when a parasite with a higher 
virulence evolves. In such cases mortality in those affected by 
malaria would be increased, hence abolishing the effectiveness 
of the vaccine.20
Alternatives to vaccination
Due to the difficulties in developing a commercially available 
malaria vaccine, other approaches to eradicate the disease need 
to be considered. 
Widespread use of insecticides has resulted in selecting 
anopheline mosquitoes that are resistant to the most affordable 
insecticides.21  Similarly, attempts to reduce the incidence of 
malaria by improved access to treatment have selected parasites 
that are resistant to the most affordable drugs.22 
There is an urgent need to find ways of re-establishing 
the efficacy of previous tools and preserving existing ones. 
Unfortunately, certain measures being adopted encourage 
further resistance. For example, when analysing the latest 
figures on malaria treatment in Africa, it can be seen that more 
Life cycle stage Stage specific antigen
 
Sporozoites Circumsporozoite protein (CSP)
  Thrombospondin-related adhesive protein (TRAP)
 
Liver stages Liver stage antigen 1 (LSA-1)
Merozoites Rhoptry-associated protein-1 (RAP-1)
  Apical membrane antigen 1 (AMA-1)
  Erythrocyte-binding antigen (EBA-175)
 
Infected red blood cell Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1)
 
Gametocytes Pfs 48/45
 
Gametes Pfg 25/27
Table 1: Surface and secreted antigens produced at the different stages of malaria life cycle.
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money is being spent on chloroquine which, although costing 
$0.10 per dose, is largely ineffective in this area. Combination 
treatments based on artemisinin would be highly effective in 
Africa, but costs at least ten times as much.23  Chloroquine use 
in such areas is also exposing patients unnecessarily to the side 
effects of the drug.
The alternatives are:
1. Use of the best available drug treatment to treat all 
malaria cases. This involves
a. choice of appropriate treatment depending upon 
the patient and resistance pattern of the parasite. 
Quinine is the recommended  drug treatment for acute 
falciparum malaria provided that the patient was not 
on any quinine-based chemoprophylaxis or living in 
areas of reported quinine resistance.24 
b. use of combination therapy to increase efficacy and 
reduce emergence of resistance. Two particularly 
promising examples are atovaquone with proguanil25 
and artemisinin-based combinations.26  The latter 
group offers an exciting prospect in the management 
of malaria and use of such combinations is advocated 
by WHO.27 
c. Use and development of alternative dosage forms and 
formulations. There is plenty of ongoing research to 
develop drug formulations that are efficacious and 
enhance patient compliance. Included are the use of 
rectal formulations of artemisinin28 and quinine29, and 
research into a transdermal mode of delivery of the 
drug.30    
2. Encourage home-based management of malaria in 
areas where treatment of uncomplicated malaria starts at 
home.31 It has been recognised that, in endemic countries, 
most episodes of malaria are first managed outside 
public health facilities, usually by the parents of affected 
children. Research has shown that a number of factors 
can improve home-based management. These include:
a. availability of unit-dose packaging of full-course 
therapy with pictorial labelling
b. training of parents and community health workers to 
recognise malarial symptoms early and treat promptly
c. Training of retailers so that they are able to offer 
appropriate antimalarial drugs at the right dosage
d. Community-targeted information, education and 
communication (IEC) for behavioural change.
3. In places where the cost of treatment is beyond reach, 
investing in prophylaxis against the disease may be 
feasible. Thus, making insecticide-impregnated mosquito 
nets widely available to the population can have a major 
impact on the incidence of the disease.32
4. Over the past years, new breeding sites for mosquitoes 
were created through deforestation, mining, irrigation 
projects and road building. These environmental changes 
might be expected to be of economic benefit to the 
country involved but will definitely lead to a worsening 
scenario in the context of malaria.33 Education, 
international help and political pressure might 
change the situation.
5. The major strategy of using insecticides to control 
the mosquito population has led to the emergence 
of insecticide-resistant mosquitoes. The high costs of 
control programmes have forced their reduction or total 
abandonment in some regions.33  Such a problem could 
be dealt with by using more than two insecticides at the 
same time. This would hopefully prevent the emergence 
of resistance, just like combined antibiotics are given to 
treat infection.19 
As it stands now, in addition to suffering and death, malaria 
penalises poor communities as it perpetuates poverty through 
loss of work force, school drop-outs and decreased financial 
investment. It is estimated that Africa’s GDP would be up to USD 
100 billion greater if malaria had been eliminated years ago.34 
Moreover, malaria could be prevented or treated for between 
$0.50 and $10.  Many of the developing countries could reduce 
malaria deaths by half if the already existing tools are wisely 
and widely used.34
The major problem here is that USD 1 billion annually 
are necessary to implement, finance and deliver the above 
recommendations. This is much more than most developing 
countries could ever aspire to afford.
Conclusion
The hard facts about malaria are far from comforting. 
Anti-malarial drugs have always been the mainstay of defence 
against the malaria parasite. If these are to remain effective, it 
is essential to track drug resistance as it appears. Also it does 
not matter how effective the next generation of anti-malarials 
are. If they are administered incorrectly, resistance soon appears 
and will annihilate a whole generation of drugs. 
Malta Medical Journal    Volume 18   Issue 02   July 2006 
The Roll Back Malaria campaign initiated by WHO has had 
some success in curbing the disease, although not all the main 
targets have been met. Thus, places, such as Vietnam have seen 
a reduction in malaria deaths by 97% in a five-year timespan. 
Similarly, in Kenya, efforts to promote the use of bednets have 
helped to reduce malaria cases.35  More research into developing 
new antimalarials, vaccines and rapid diagnostic methods is 
required to halt the progress of such a devastating disease.
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